Steven A. Kaplan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven A. Kaplan has a total of 297 co-authors. Here are the top co-authors by number of shared publications:
Bilal Chughtai
Weill Cornell Medical Center, New York, USA
14 shared publicationsAlan G. Meehan
Merck & Co., Inc., Kenilworth, New Jersey
9 shared publications- Alexis E. Te
Icahn School of Medicine at Mount Sinai, New York, USA
9 shared publications - Bilal Chughtai
Department of Urology, Northwell Health, Syosset, NY 11791, USA
9 shared publications - Dean Elterman
Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada
9 shared publications Alexis E. Te
Cornell University, USA
8 shared publications
Latest Publications
- 13 August 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 559
Recalibrating sham-relative superiority thresholds in BPH device trials
- 13 August 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 559
Recalibrating sham-relative superiority thresholds in BPH device trials
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (6) , 759-761
Benign Prostatic Hyperplasia
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (6) , 759-761
Benign Prostatic Hyperplasia
- 6 April 2026
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (4) , 1-6
Practical management of hematuria after endoscopic surgery for benign prostatic obstruction
Postoperative hematuria following transurethral prostate procedures ranges from self-limited bleeding to life-threatening hemorrhage. Clinically significant hematuria occurs in approximately 13–22% of patients after transurethral resection of the prostate (TURP), with clot retention in 1–5%. Bleeding risk increases with prostate size, and transfusion rates approach 9% for glands exceeding 60 g. This perspective synthesizes current evidence on the prevention and management of postoperative hematuria across transurethral prostate procedures, including standard TURP, laser techniques, and office-based minimally invasive surgical treatments (MISTs). Prevention begins preoperatively with risk stratification, anticoagulation management, and consideration of 5α-reductase inhibitors to reduce prostatic vascularity. Intraoperatively, bipolar energy and laser vaporization provide improved hemostasis compared with monopolar resection, while MISTs such as UroLift and Rezūm carry distinct bleeding profiles that warrant tailored postoperative management. Postoperative management follows a stepwise approach: large-lumen catheterization with continuous bladder irrigation, balloon traction for tamponade, antispasmodics for bladder spasm control, and tranexamic acid for pharmacologic hemostasis. Surgical escalation with cystoscopic clot evacuation, fulguration, or prostatic artery embolization is reserved for refractory cases. We present a device-agnostic outpatient workflow (Figure 1) applicable to ambulatory and office-based procedures. Most patients recover with conservative measures, and protocolized care improves safety and outcomes. Future research should focus on standardizing management pathways, identifying predictors of clinically significant bleeding, and exploring the role of AI-based risk stratification and novel hemostatic agents.
- 6 April 2026
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (4) , 1-6
Practical management of hematuria after endoscopic surgery for benign prostatic obstruction
Postoperative hematuria following transurethral prostate procedures ranges from self-limited bleeding to life-threatening hemorrhage. Clinically significant hematuria occurs in approximately 13–22% of patients after transurethral resection of the prostate (TURP), with clot retention in 1–5%. Bleeding risk increases with prostate size, and transfusion rates approach 9% for glands exceeding 60 g. This perspective synthesizes current evidence on the prevention and management of postoperative hematuria across transurethral prostate procedures, including standard TURP, laser techniques, and office-based minimally invasive surgical treatments (MISTs). Prevention begins preoperatively with risk stratification, anticoagulation management, and consideration of 5α-reductase inhibitors to reduce prostatic vascularity. Intraoperatively, bipolar energy and laser vaporization provide improved hemostasis compared with monopolar resection, while MISTs such as UroLift and Rezūm carry distinct bleeding profiles that warrant tailored postoperative management. Postoperative management follows a stepwise approach: large-lumen catheterization with continuous bladder irrigation, balloon traction for tamponade, antispasmodics for bladder spasm control, and tranexamic acid for pharmacologic hemostasis. Surgical escalation with cystoscopic clot evacuation, fulguration, or prostatic artery embolization is reserved for refractory cases. We present a device-agnostic outpatient workflow (Figure 1) applicable to ambulatory and office-based procedures. Most patients recover with conservative measures, and protocolized care improves safety and outcomes. Future research should focus on standardizing management pathways, identifying predictors of clinically significant bleeding, and exploring the role of AI-based risk stratification and novel hemostatic agents.
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (4) , 421-430
12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia
The ProVee System for BPH is a new generation permanent prostatic urethral stent for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. ProVIDE is a prospective, randomized, double-blind, sham controlled study evaluating the safety and effectiveness of ProVee against a sham procedure. Men at least 45 years of age were eligible for the study if they had International Prostate Symptom Score ≥13, peak urinary flow rate 25% mean improvement in International Prostate Symptom Score over sham at 3 months (9.5 versus 5.6, p=0.001) and a >30% mean improvement from baseline to 12 months in the ProVee arm (37.8%, p=0.002). There were no device or procedure related serious adverse events through 12 months and no incidence of de novo sustained retrograde ejaculation or erectile dysfunction. Treatment with ProVee was reliably performed and resulted in a statistically superior improvement in IPSS at 3 months compared to a sham procedure with sustained response at 12 months.
- 1 April 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (4) , 421-430
Open Access12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia
The ProVee System for BPH is a new generation permanent prostatic urethral stent for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. ProVIDE is a prospective, randomized, double-blind, sham controlled study evaluating the safety and effectiveness of ProVee against a sham procedure. Men at least 45 years of age were eligible for the study if they had International Prostate Symptom Score ≥13, peak urinary flow rate 25% mean improvement in International Prostate Symptom Score over sham at 3 months (9.5 versus 5.6, p=0.001) and a >30% mean improvement from baseline to 12 months in the ProVee arm (37.8%, p=0.002). There were no device or procedure related serious adverse events through 12 months and no incidence of de novo sustained retrograde ejaculation or erectile dysfunction. Treatment with ProVee was reliably performed and resulted in a statistically superior improvement in IPSS at 3 months compared to a sham procedure with sustained response at 12 months.
- 6 March 2026
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (4) , 1-11
Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes
Purpose We systematically reviewed the long-term outcomes of untreated prostate cancer across different risk categories to inform treatment decisions and active surveillance protocols. This comprehensive analysis synthesizes long-term progression data across tumor staging and grading systems. Materials and methods We conducted a systematic literature search of PubMed, EMBASE, and Cochrane databases (1990–2025) for studies reporting ≥10-year outcomes in untreated or conservatively managed prostate cancer patients. Eligible studies included observational cohorts, population registries, and meta-analyses. Primary endpoints included prostate cancer-specific mortality, metastatic progression, and competing mortality. Results Fifteen major studies encompassing 43,127 patients (median follow-up 15–30 years) demonstrated heterogeneous progression patterns. Ten-year prostate cancer-specific survival ranged from >95% for Gleason 6 tumors to <60% for Gleason 8–10 disease. Grade Group 1 tumors showed <5% metastatic risk over 15–20 years, while Grade Groups 4–5 exhibited rapid progression with median disease-specific survival <5 years. Across all risk groups, disease progression accelerated markedly after 15 years. Men diagnosed after age 75 faced substantial competing mortality (~57–60% 10-year non-cancer mortality), regardless of tumor grade. Conclusions Tumor grade is the strongest prognostic factor in the natural history of untreated prostate cancer. Low-grade disease often remains indolent for 15–20 years, whereas high-grade tumors frequently progress to lethal disease within a few years, warranting early intervention. These findings support contemporary active surveillance protocols for low-risk patients and inform evidence-based treatment decisions for higher-risk disease. Summary with methodological context:
- 6 March 2026
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 29 (4) , 1-11
Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes
Purpose We systematically reviewed the long-term outcomes of untreated prostate cancer across different risk categories to inform treatment decisions and active surveillance protocols. This comprehensive analysis synthesizes long-term progression data across tumor staging and grading systems. Materials and methods We conducted a systematic literature search of PubMed, EMBASE, and Cochrane databases (1990–2025) for studies reporting ≥10-year outcomes in untreated or conservatively managed prostate cancer patients. Eligible studies included observational cohorts, population registries, and meta-analyses. Primary endpoints included prostate cancer-specific mortality, metastatic progression, and competing mortality. Results Fifteen major studies encompassing 43,127 patients (median follow-up 15–30 years) demonstrated heterogeneous progression patterns. Ten-year prostate cancer-specific survival ranged from >95% for Gleason 6 tumors to <60% for Gleason 8–10 disease. Grade Group 1 tumors showed <5% metastatic risk over 15–20 years, while Grade Groups 4–5 exhibited rapid progression with median disease-specific survival <5 years. Across all risk groups, disease progression accelerated markedly after 15 years. Men diagnosed after age 75 faced substantial competing mortality (~57–60% 10-year non-cancer mortality), regardless of tumor grade. Conclusions Tumor grade is the strongest prognostic factor in the natural history of untreated prostate cancer. Low-grade disease often remains indolent for 15–20 years, whereas high-grade tumors frequently progress to lethal disease within a few years, warranting early intervention. These findings support contemporary active surveillance protocols for low-risk patients and inform evidence-based treatment decisions for higher-risk disease. Summary with methodological context:
- 21 February 2026
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS
Generic competition has markedly reduced the cost of medications for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), potentially reshaping the value proposition of first-line therapy. We reviewed contemporary drug pricing and health-economic evidence to evaluate the cost-effectiveness of medical therapy as initial management for BPH/LUTS. We synthesized evidence from randomized trials, meta-analyses, international guidelines, and published cost-effectiveness/cost-utility analyses comparing pharmacotherapy with common minimally invasive and surgical BPH interventions. Common generic agents (e.g., tamsulosin and finasteride) are available for approximately $2-$7 per month through discount programs. Clinical trial evidence demonstrates meaningful symptom improvement and reduced risk of progression with alpha-blockers and 5-alpha-reductase inhibitors, particularly in combination therapy. Published economic models consistently show favorable incremental cost-effectiveness ratios for medical management versus watchful waiting or surgery; under current generic pricing, medication costs rarely approach the one-time costs of procedural interventions within a typical lifespan. Contemporary clinical and economic evidence supports medical therapy as a highly cost-effective first-line treatment for BPH/LUTS, with procedural interventions best reserved for medication failure, complications, or patient preference.
- 21 February 2026
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS
Generic competition has markedly reduced the cost of medications for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), potentially reshaping the value proposition of first-line therapy. We reviewed contemporary drug pricing and health-economic evidence to evaluate the cost-effectiveness of medical therapy as initial management for BPH/LUTS. We synthesized evidence from randomized trials, meta-analyses, international guidelines, and published cost-effectiveness/cost-utility analyses comparing pharmacotherapy with common minimally invasive and surgical BPH interventions. Common generic agents (e.g., tamsulosin and finasteride) are available for approximately $2-$7 per month through discount programs. Clinical trial evidence demonstrates meaningful symptom improvement and reduced risk of progression with alpha-blockers and 5-alpha-reductase inhibitors, particularly in combination therapy. Published economic models consistently show favorable incremental cost-effectiveness ratios for medical management versus watchful waiting or surgery; under current generic pricing, medication costs rarely approach the one-time costs of procedural interventions within a typical lifespan. Contemporary clinical and economic evidence supports medical therapy as a highly cost-effective first-line treatment for BPH/LUTS, with procedural interventions best reserved for medication failure, complications, or patient preference.
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (1) , 94-96
Benign Prostatic Hyperplasia
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (1) , 94-96
Benign Prostatic Hyperplasia
- 2 September 2025
- Published by Elsevier in Urologic Clinics of North America
- Vol. 52 (4)
The Dynamic Changes Occurring in the Diagnosis and Treatment of Benign Prostatic Hyperplasia
- 2 September 2025
- Published by Elsevier in Urologic Clinics of North America
- Vol. 52 (4)
The Dynamic Changes Occurring in the Diagnosis and Treatment of Benign Prostatic Hyperplasia
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of Urology
Benign Prostatic Hyperplasia